Key result
Non-vitamin K antagonist oral anticoagulants were the most common initial therapy for VTE, with 3-month persistence rates of 62.9% in patients without active cancer and 57.2% in those with active cancer.
Why the study?
Comprehensive utilization of anticoagulation therapy in patients with VTE, particularly regarding active cancer, remains unclear in real-world practice.
What are the real-world prescription patterns and persistence of anticoagulation therapy in patients with VTE, stratified by active cancer status?
Cohort (n=55,759)
What are the real-world prescription patterns and persistence of anticoagulation therapy in patients with VTE, stratified by active cancer status?
Absolute Event Rate: 62.9% vs 60.8%
p-value: p=<0.0001
In South Korea, NOACs have become the predominant anticoagulation therapy for VTE regardless of cancer status, though persistence remains suboptimal and varies by cancer status and drug type.
NOAC persistence ~60% at 3 months in VTE may signal adherence gaps; leaves open cancer-specific barriers in real-world cohorts.
BACKGROUND: Venous thromboembolism (VTE) is associated with increased morbidity, mortality, and health care expenditure. However, the comprehensive utilization of anticoagulation therapy in patients with VTE, especially regarding active cancer, in real-world practice remains unclear. OBJECTIVE: To describe the prescription, persistence, and patterns of anticoagulation therapy among patients with VTE stratified according to active cancer. METHODS: Using Korean nationwide claims data, we identified an incident, treatment-naïve cohort of patients with VTE from 2013 to 2019 and classified them according to the presence/absence of active cancer. We explored the secular trends, treatment patterns (e.g., discontinuation, interruption, and switch), and persistence of anticoagulation therapy. RESULTS: There were 48,504 and 7,255 patients without and with active cancer, respectively. Non-vitamin K antagonist oral anticoagulants (NOACs) were the most common anticoagulant in both groups (65.1 and 57.9%, respectively). The prescription of NOACs increased steeply over time, regardless of active cancer, whereas parenteral anticoagulants (PACs) plateaued and warfarin decreased sharply. A heterogeneous pattern was observed between the groups without and with active cancer (3-month persistence was 60.8, 62.9, 57.2, and 3.4%, respectively; 6-month persistence was 42.3, 33.5, 25.9, and 1.2% vs. 9.9%). Median durations of continuous anticoagulant therapy for warfarin, NOAC, and PAC were 183, 147, and 3 days in nonactive cancer patients, and 121, 117, and 44 days in active cancer patients. CONCLUSION: Our findings suggest that there were substantial differences in persistence, patterns, and patient characteristics of anticoagulant therapy based on index anticoagulant and active cancer.
No takes yet. Share an insight, caveat, or question.
Yoon et al. (2023) conducted a cohort in Venous thromboembolism (n=55,759). Non-vitamin K antagonist oral anticoagulants (NOACs) vs. Warfarin or parenteral anticoagulants was evaluated on 3-month treatment persistence (NOACs vs Warfarin in non-active cancer patients) (p=<0.0001). Non-vitamin K antagonist oral anticoagulants were the most common initial therapy for VTE, with 3-month persistence rates of 62.9% in patients without active cancer and 57.2% in those with active cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: